Ilaris Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited effectiveness of traditional anti inflammatory drugs, historical unmet needs in caps patients, early biologic approvals, specialist driven prescribing, rising awareness of autoinflammatory syndromes.

The growth in the forecast period can be attributed to expansion of precision immunology research, increasing diagnosis of rare inflammatory diseases, growing biologics reimbursement coverage, advancements in cytokine targeting therapies, growth of specialty rheumatology centers. Major trends in the forecast period include expansion of il-1 targeted therapies, rising focus on autoinflammatory disorders, growth in biologic treatments for rare diseases, increasing long term inflammation control, improved quality of life outcomes.

The increasing prevalence of inflammatory diseases is expected to drive the growth of the Ilaris market. Inflammatory diseases are conditions where the body’s immune system triggers inflammation in tissues, leading to pain, swelling, and potential damage. The rise in inflammatory diseases can be attributed to factors such as aging populations, environmental triggers, lifestyle changes, genetic predispositions, and an increase in autoimmune disorders. Ilaris is used to treat inflammatory diseases like cryopyrin-associated periodic syndromes (CAPS) by inhibiting interleukin-1β, which reduces inflammation and associated symptoms. For example, in September 2023, a report from the National Library of Medicine (NLM), a US-based medical library, stated that the incidence of inflammatory bowel disease (IBD) in Canada was 30 per 100,000, resulting in approximately 11,000 new diagnoses in 2023. The incidence is projected to increase by 0.58% annually, reaching 32.1 per 100,000 by 2035. Therefore, the growing prevalence of inflammatory diseases is driving the expansion of the Ilaris market.

The rising geriatric population is expected to further boost the growth of the Ilaris market. The geriatric population refers to individuals aged 65 and older, a demographic group that is increasing due to advancements in healthcare, improved living standards, and longer life expectancy, along with declining birth rates. Ilaris plays a crucial role in the treatment of chronic inflammatory conditions, such as gout flares and autoinflammatory diseases, particularly in older patients who may face challenges with traditional therapies due to age-related health issues. For instance, in October 2024, the World Health Organization (WHO) projected that the number of people aged 60 and older would increase from 1 billion in 2020 to 1.4 billion by 2030, making up one in six of the global population. By 2050, this number is expected to reach 2.1 billion, a twofold increase, with the population aged 80 and older predicted to triple, reaching 426 million. Therefore, the growing geriatric population will continue to drive the Ilaris market.

A key trend in the Ilaris market is the development of innovative products, such as biologic therapies, to prevent, diagnose, or treat diseases. Biologic therapy uses substances derived from living organisms to target specific components of the immune system in disease treatment. For example, in August 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) had approved Ilaris (canakinumab) for treating gout flares in adults. This approval is for patients who cannot tolerate NSAIDs, colchicine, or repeated corticosteroid courses, or for whom these treatments are ineffective. As the first biologic therapy approved for gout flares, Ilaris offers a novel option for managing this painful condition. The decision was based on phase 3 clinical trials, which showed significant reductions in pain intensity and flare recurrence, with no unexpected safety issues reported.

Major companies operating in the ilaris market are Novartis AG.

North America was the largest region in the ilaris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ilaris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ilaris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the ilaris market by increasing costs associated with monoclonal antibody manufacturing, bioprocessing equipment, and temperature sensitive logistics. These impacts are most evident across hospital and specialty clinic distribution channels, particularly in regions reliant on imported biologics such as asia pacific and latin america. Higher tariffs can affect treatment affordability and delay patient access to advanced immunotherapies. However, tariffs are also encouraging localized biologics production, regional supply chain strengthening, and long term investments in domestic pharmaceutical manufacturing capabilities.

The ilaris market research report is one of a series of new reports that provides ilaris market statistics, including ilaris industry global market size, regional shares, competitors with a ilaris market share, detailed ilaris market segments, market trends and opportunities, and any further data you may need to thrive in the ilaris industry. This ilaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ilaris (canakinumab) is a monoclonal antibody medication used to treat various inflammatory diseases, including certain rare autoinflammatory disorders. It works by targeting and inhibiting interleukin-1 beta (IL-1β), a cytokine involved in inflammatory responses. Ilaris is approved for conditions such as cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and systemic juvenile idiopathic arthritis (SJIA). By reducing inflammation, it helps prevent the severe symptoms and complications associated with these diseases, improving the quality of life for patients who do not respond to traditional treatments.

The primary patient demographics for Ilaris include both pediatric and adult patients. Pediatric patients are individuals under the age of 18, who typically require specialized medical care tailored to their developmental needs. Ilaris is distributed through hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is used for treating cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, gout, and other inflammatory conditions.

The ilaris market consists of sales of secukinumab, erenumab, and dabrafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.